Resources

Chris Molloy on investment for BIA members; TIME’s Best Inventions; MHRA 2030 Strategy; Rare disease medicines review; Party conferences; TechBio; and BIA's AGM

Chris Molloy on investment in dementia; AI in healthcare; TechBio; BioJapan; bioProcessUK; Green, Conservative and Labour conferences; and BIA Board elections

Chris Molloy on the Labour Party conference; female biotech leaders in Edinburgh; Women in Biotech mentoring programme; Advanced Therapy Treatment Centre; BioSolutions Advisory Board; TechBio UK; and careers at BIA

£135 million for two life sciences funds, rare disease R&D, Beacon Therapeutics, Basecamp Research’s Series C, Birmingham Life Sciences Week, Liberal Democrat party conference, Women in Biotech Edinburgh

Regional cluster updates, fresh OLS data, NICE's Enhertu approval and £89.9m for Chemify - catch up on this week's CEO blog.

Autumn Budget, AI regulation and new transatlantic partnerships: how we’re driving scale and capital for UK biotechs.

The advantages to building a business in the UK's biotech clusters

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Chris Molloy on what the new Government means for the sector, a farewell to Lord Patrick Vallance, gene synthesis screening and TechBio UK early bird tickets

Chris Molloy on the Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

How to unlock the UK's innovative life sciences and biotech potential

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

Discover how BIA members influenced the UK Life Sciences Sector Jobs Plan, addressing critical biotech talent shortages, lab skills and AI innovation